title: A proposal of new therapeutic strategy for antenatally diagnosed congenital diaphragmatic hernia.
abstract: OBJECTIVE
  The prognosis of antenatally diagnosed congenital diaphragmatic hernia (ADCDH) is still very poor despite of innovation of various therapeutics. The authors reviewed their new therapeutic strategy of ADCDH from a viewpoint of cardiologic function.
  
  
  METHODS
  The cardiac function in 19 cases of ADCDH was reviewed. The patients, at the age of 0 days, were divided into 2 groups, PG (+) and PG (-), according to the requirement of prostaglandin E1 (PGE1) to attenuate pulmonary hypertension. The left ventricular (LV) end-diastolic dimension (LV diastolic diameter index [LVDI]) and bilateral pulmonary arterial diameters (total pulmonary artery index [TPAI]) were measured on days 0 and 2.
  
  
  RESULTS
  Only 1 patient died of cardiac or respiratory failure, and the survivors' postoperative course was uneventful. Eleven patients needed inhalation of nitric oxide (NO), and in 9 of those, PGE1 was administered. The LVDI and TPAI of day 0 in PG (+) were significantly smaller than those in PG (-) and the controls. The LVDI increased from postnatal day 0 to day 2 in both PG (+) and PG (-). Although the LV was too small to output enough volume, the right ventricle successfully compensated for the low output through the ductus arteriosus, kept patent by NO and PGE1.
  
  
  CONCLUSIONS
  For ADCDH with sever pulmonary hypertension, keeping patent ductus arteriosus with NO and PGE1 plays a critical role in obtaining excellent clinical outcome. Thus, the authors proposed a new therapeutic strategy for ADCDH based on a circulatory management.
authors.affiliation: Department of Pediatric Cardiology, Osaka Medical Center and Research Institute for Maternal and Child Health, Osaka 594-1101, Japan. inamura@mch.pref.osaka.jp
authors.forename: Noboru
authors.initials: N
authors.lastname: Inamura
authors.forename: Akio
authors.initials: A
authors.lastname: Kubota
authors.forename: Tohru
authors.initials: T
authors.lastname: Nakajima
authors.forename: Futoshi
authors.initials: F
authors.lastname: Kayatani
authors.forename: Hiroomi
authors.initials: H
authors.lastname: Okuyama
authors.forename: Takaharu
authors.initials: T
authors.lastname: Oue
authors.forename: Hisayoshi
authors.initials: H
authors.lastname: Kawahara
mesh_terms: D000527:Alprostadil / Q000494:pharmacology / Q000627:therapeutic use; D004373:Ductus Arteriosus / Q000187:drug effects* / Q000502:physiology; D004452:Echocardiography; D005260:Female; D006548:Hernia, Diaphragmatic / Q000150:complications / Q000000981:diagnostic imaging / Q000628:therapy*; D065630:Hernias, Diaphragmatic, Congenital; D006801:Humans; D006976:Hypertension, Pulmonary / Q000209:etiology / Q000517:prevention & control; D007231:Infant, Newborn; D009569:Nitric Oxide / Q000494:pharmacology / Q000627:therapeutic use*; D010547:Persistent Fetal Circulation Syndrome / Q000209:etiology / Q000503:physiopathology*; D011247:Pregnancy; D011651:Pulmonary Artery / Q000187:drug effects / Q000473:pathology; D012127:Respiratory Distress Syndrome, Newborn / Q000188:drug therapy* / Q000209:etiology; D016216:Ultrasonography, Prenatal; D014665:Vasodilator Agents / Q000627:therapeutic use; D018754:Ventricular Dysfunction / Q000503:physiopathology
chemical_list: D014665:Vasodilator Agents; D009569:Nitric Oxide; D000527:Alprostadil